Advertisement

Amphotericin B Cholesteryl Sulfate Complex Injection

[12 April 2013]

Products Affected - Description

Amphotec, lyophilized powder, Alkopharma
50 mg vial (NDC 66435-0301-51)
100 mg vial (NDC 66435-0302-01)

Reason for the Shortage

  • Kadmon had acquired Three Rivers Pharmaceuticals in October 2010 and Amphotec was part of the product portfolio.
  • Kadmon recently sold Amphotec to Alkopharma. Alkopharma is the sole supplier of amphotericin b cholesteryl sulfate lipid complex. The current contracted manufacturer of Amphotec is Ben Venue Laboratories. Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis. It is unknown when manufacturing will resume.
  • The shortage of amphotericin b cholesteryl sulfate lipid complex is not affecting other amphotericin formulations.

Available Products

No presentations are available.

Estimated Resupply Dates

Amphotec is not expected to be available from Alkopharma until after manufacturing is restored by Ben Venue Labs. Updated availability information from Alkopharma is not available.

Related Shortages

Updated

April 12, 2013; February 13, 2013; September 10, 2012; July 6, 2012; February 15, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity

Get the latest updates on ASHP's advocacy activity on drug shortages.



In Cooperation With

University of Utah & Novation
Advertisement